Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated

Benzinga · 1d ago
  • Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint
  • Consistent with prior studies, VQW-765 was safe and well tolerated

WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint.